非小细胞肺癌患者血清sICAM-1、sVCAM-1水平的临床意义

Serum Level of sICAM-1and sVCAM-1in Patients with Non-Small Cell Lung Cancer

目的:探讨血清sICAM-1,sVCAM-1水平测定在非小细胞肺癌中的临床意义。方法:应用ELISA法测定43例非小细胞肺癌患者(其中14例为化疗后患者)血清sICAM-1、sVCAM-1的浓度,并与正常人比较。结果:Ⅰ+Ⅱ期、Ⅲ+Ⅳ期肺癌患者sICAM-1的浓度分别为370.65±78.63ng/ml、550.88±343.31ng/ml均明显高于正常组(P<0.01),且Ⅲ+Ⅳ期患者的sICAMV-1与Ⅰ+Ⅱ期比较具有显著性差异(P<0.05),Ⅰ+Ⅱ期、Ⅲ+Ⅳ期肺癌患者sVCAM-1的浓度分别为543.92±142.37ng/ml、885.12±892.12ng/ml均明显高于正常组(P<0.01),且二者之间也存在差异(P<0.05)。14例化疗后的患者sICAM-1、sVCAM-1分别为351.78±161.80ng/ml、418.64±251.64ng/ml均明显低于化疗前(P<0.05,P<0.01)。结论:血清sICAM-1,sVCAM-1水平与肺癌的病情发展相关,并有可能作为肺癌化疗评价疗效的血清学指标之一。

Obj ec tive:To explore the clinical significance of detecting sICAM-1and sV-CAM-1 in non-small cell lung cancer(NSCLC)patients.Methods:Forty-three lung canc er patients and18healthy subjects were evaluated.Fourteen of43cases receive d chemotherapy.The levels of serum sICAM-1and sVCAM-1were measured by ELISA .Results:The sICAM-1serum concentration of lung cancer patients in stageⅠ? Ⅱ(370.65±78.63ng /ml )and stageⅢ?Ⅳ(550.88±343.3 1ng /ml)were significantly higher than those of the control group (P<0.0 1),and the differences among stageⅠ～Ⅱand stageⅢ?Ⅳwere significant (P< 0.05).The mean value of sV-CAM-1in early stage(Ⅰ～Ⅱ)patients and ad vanced clinical stage(Ⅲ～Ⅳ)patients were543.92±142.37ng /ml a nd885.12±892.12ng /ml respectively,which was obviously higher th an that in the control group(P<0.01).The latter was significantly differ ed from the early stage(Ⅰ～Ⅱ)patients(P<0.05)?The serum sICAM-1?s VCAM-1in14cases received chemotherapy were obviously de-creased(P<0.0 5,P<0.01)?Conclusion:The serum levels of sICAM-1,sVCAM-1are corre lated with the clinical stage of the patients with NSCLC.Serum levels of sCAM-1?sVCAM-1may be a valuable parameter for predicting the effect of chemothera py.